Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int Immunopharmacol ; 31: 239-47, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26773771

ABSTRACT

meso-Dihydroguaiaretic acid (MDGA), which is a dibenzylbutane lignin isolated from the ethyl acetate fraction of Saururus chinensis, has various biological activities, including anti-oxidative, anti-inflammatory, anti-bacterial, and neuroprotective effects. However, no report has examined the potential anti-asthmatic activity of MDGA. In this study, we evaluated the protective effects of MDGA on asthmatic responses, particularly airway inflammation and mucus hypersecretion in an ovalbumin (OVA)-induced murine model of asthma. Intragastric administration of MDGA significantly lowered the productions of interleukin (IL)-4, IL-5, IL-13, tumor necrosis-α (TNF-α), eotaxin, monocyte chemoattractant protein-1 (MCP-1), vascular cell adhesion molecule-1 (VCAM-1), and immunoglobulin (Ig)E in bronchoalveolar lavage fluid (BALF), plasma, or lung tissues. Histological studies showed that MDGA inhibited OVA-induced inflammatory cell infiltration and mucus production in the respiratory tract. Moreover, MDGA markedly attenuated the OVA-induced activations of nuclear factor kappa B (NF-κB), extracellular-signal-regulated kinases 1/2 (ERK1/2), and p38 mitogen-activated protein kinase (p38 MAPK). Together, these results suggest that MDGA effectively inhibits airway inflammation and mucus hypersecretion by downregulating the levels of T helper 2 (Th2) cytokines, chemokines, and adhesion molecules, and inhibiting the activations of NF-κB and MAPKs.


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Guaiacol/analogs & derivatives , Lignans/therapeutic use , Pneumonia/drug therapy , Saururaceae/immunology , Animals , Cell Movement/drug effects , Chemokine CCL2/metabolism , Cytokines/metabolism , Female , Guaiacol/therapeutic use , Humans , Immunoglobulin E/metabolism , MAP Kinase Signaling System/drug effects , Mice , Mice, Inbred BALB C , NF-kappa B/metabolism , Th2 Cells/immunology , Vascular Cell Adhesion Molecule-1/metabolism
2.
Int Immunopharmacol ; 17(2): 471-7, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23928505

ABSTRACT

Previous studies have shown that sauchinone modulates the expression of inflammatory mediators through mitogen-activated protein kinase (MAPK) pathways in various cell types. However, little information exists about the effect of sauchinone on neutrophils, which play a crucial role in inflammatory process such as acute lung injury (ALI). We found that sauchinone decreased the phosphorylation of p38 MAPK in lipopolysaccharide (LPS)-stimulated murine bone marrow neutrophils, but not ERK1/2 and JNK. Exposure of LPS-stimulated neutrophils to sauchinone or SB203580, a p38 inhibitor, diminished production of tumor necrosis factor (TNF)-α and macrophage inflammatory protein (MIP)-2 compared to neutrophils cultured with LPS. Treatment with sauchinone decreased the level of phosphorylated ribosomal protein S6 (rpS6) in LPS-stimulated neutrophils. Systemic administration of sauchinone to mice led to reduced levels of phosphorylation of p38 and rpS6 in mice lungs given LPS, decreased TNF-α and MIP-2 production in bronchoalveolar lavage fluid, and also diminished the severity of LPS-induced lung injury, as determined by reduced neutrophil accumulation in the lungs, wet/dry weight ratio, and histological analysis. These results suggest that sauchinone diminishes LPS-induced neutrophil activation and ALI.


Subject(s)
Acute Lung Injury/drug therapy , Benzopyrans/administration & dosage , Dioxoles/administration & dosage , Inflammation Mediators/metabolism , Lignans/administration & dosage , Macrophages/drug effects , Neutrophils/drug effects , Saururaceae/immunology , Acute Lung Injury/immunology , Animals , Benzopyrans/therapeutic use , Cell Movement/drug effects , Cells, Cultured , Chemokine CXCL2/metabolism , Cytokines/metabolism , Dioxoles/therapeutic use , Lipopolysaccharides/immunology , MAP Kinase Signaling System/drug effects , Macrophages/immunology , Male , Mice , Mice, Inbred BALB C , Neutrophils/immunology , Phosphorylation , Ribosomal Protein S6/metabolism , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
3.
Int Immunopharmacol ; 11(6): 698-705, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21295171

ABSTRACT

Chronic airway inflammation is a hallmark of asthma, which is an immune-based disease. We evaluated the ability of saucerneol D, a tetrahydrofuran-type sesquilignan isolated from Saururus chinensis, to regulate airway inflammation in an ovalbumin (OVA)-induced airway inflammation model. Furthermore, we determined whether heme oxygenase (HO)-1 was required for the protective activity of saucerneol D. The airways of OVA-sensitized mice exposed to an OVA challenge developed eosinophilia and mucus hypersecretion and exhibited increased cytokine levels. Mice were administered saucerneol D orally at doses of 20 and 40mg/kg once daily on days 26-30. Saucerneol D administered orally significantly inhibited the number of OVA-induced inflammatory cells and the production of immunoglobulin E as well as Th2-type cytokines. Histopathology studies revealed a marked decrease in lung inflammation and goblet cell hyperplasia after saucerneol D treatment. In addition, saucerneol D induced HO-1 and led to a marked decrease in OVA-induced reactive oxygen species and malondialdehyde and an increase in superoxide dismutase and glutathione in lung tissues. These antioxidant effects were correlated with HO-1 induction. In our experiments, saucerneol D treatment reduced airway inflammation and suppressed oxidative stress in an OVA-induced asthma model.


Subject(s)
Anti-Asthmatic Agents/administration & dosage , Antioxidants/administration & dosage , Asthma/drug therapy , Lignans/administration & dosage , Pneumonia/drug therapy , Animals , Anti-Asthmatic Agents/chemistry , Antioxidants/chemistry , Asthma/immunology , Cells, Cultured , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Female , Heme Oxygenase (Decyclizing)/genetics , Heme Oxygenase (Decyclizing)/metabolism , Humans , Immunoglobulin E/biosynthesis , Immunoglobulin E/blood , Immunoglobulin E/genetics , Lignans/chemistry , Lignans/pharmacology , Mice , Mice, Inbred BALB C , Pneumonia/chemically induced , Pneumonia/immunology , Reactive Oxygen Species/metabolism , Saururaceae/immunology , Th1-Th2 Balance/drug effects
4.
Mol Cells ; 20(1): 105-11, 2005 Aug 31.
Article in English | MEDLINE | ID: mdl-16258248

ABSTRACT

Mannasantin B, a dilignan structurally related to manssantin A, is an inhibitor of NF-kappaB transactivation. In the present study, we found that it inhibited PMA-induced expression of IL-1beta, IL-1beta mRNA, and IL-1beta promoter activity in U937 cells with IC50 values of about 50 nM. It also inhibited NF-IL6- and NF-kappaB-induced activation of IL-1beta, with IC50 values of 78 nM and 1.6 microM, respectively, revealing a potent inhibitory effect on NF-IL6. Electrophoretic mobility shift assays showed that manassantin B had an inhibitory effect on DNA binding by NF-IL6, but not by NF-kappaB. Further analysis revealed that transactivation by NF-IL6 was also inhibited. Our results indicate that manassantin B suppresses expression of IL-1beta in promonocytic cells by inhibiting not only NF-kappaB but also NF-IL6 activity. Furthermore, our observations suggest that manassantin B may be clinically useful as a potent inhibitor of NF-IL6 activity.


Subject(s)
CCAAT-Enhancer-Binding Protein-beta/metabolism , Furans/pharmacology , Saururaceae/metabolism , Tetradecanoylphorbol Acetate/antagonists & inhibitors , Dose-Response Relationship, Drug , Electrophoretic Mobility Shift Assay , Humans , Inhibitory Concentration 50 , Interleukin-1/genetics , Interleukin-1/metabolism , Saururaceae/genetics , Saururaceae/immunology , Transcriptional Activation/drug effects , Transfection , U937 Cells
SELECTION OF CITATIONS
SEARCH DETAIL
...